Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

German artificial heart project to aid reimbursement:

This article was originally published in Clinica

Executive Summary

In an effort to increase awareness of new therapies developed to treat heart problems, the German medical device industry association, BVMed, has set up a new ventricular assist services/artificial heart project group, VAD/Kunstherz. Major aims of the group include introducing therapeutic possibilities to doctors and disseminating information to medical decision makers. "Numerous lives could thus be saved because there are not enough donor hearts available in Germany and almost a third of patients awaiting transplantation die before one becomes available," says the association. BVMed hopes that this initiative will speed up the entry of such therapies into the catalogue of reimbursable procedures under the new diagnosis related groups (DRG) system. A study recently published in the Journal of the American College of Cardiology said that heart transplant patients who receive implantable mechanical heart pumps until donor hearts become available have a better chance of survival and lower post transplant death rates than those relying on medication.

You may also be interested in...



Investors Go Berserk For Viking, Putting It Top Of Q1 Winners

The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.

EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications

Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.

Industry & Regulators To Align Advice on COVID-19 Vaccine Updates

A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT066084

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel